Vestal Point Capital, LP Immatics N.V. Transaction History
Vestal Point Capital, LP
- $1.9 Trillion
- Q2 2025
A detailed history of Vestal Point Capital, LP transactions in Immatics N.V. stock. As of the latest transaction made, Vestal Point Capital, LP holds 6,250,000 shares of IMTX stock, worth $40.1 Million. This represents 1.77% of its overall portfolio holdings.
Number of Shares
6,250,000
Previous 7,192,700
13.11%
Holding current value
$40.1 Million
Previous $32.4 Billion
3.66%
% of portfolio
1.77%
Previous 2.32%
Shares
7 transactions
Others Institutions Holding IMTX
# of Institutions
73Shares Held
93.6MCall Options Held
158KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD18.3MShares$118 Million0.06% of portfolio
-
Suvretta Capital Management, LLC New York, NY12MShares$77.2 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY10.2MShares$65.3 Million0.55% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$60.2 Million2.22% of portfolio
-
Rtw Investments, LP New York, NY6.97MShares$44.7 Million0.58% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $489M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...